On March 3, 2021 Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, reported that Viracta will participate at the H.C. Wainwright Global Life Sciences Conference, being held March 9-10, 2021 (Press release, Viracta Therapeutics, MAR 3, 2021, View Source [SID1234576042]). A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on March 9, 2021. Viracta’s management team will also be available for one-on-one investor meetings at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!